SINGAPORE, July 19, 2024 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has signed a 10-year commercialization partnership with Austria-based Institut AllergoSan. Institut AllergoSan is a research and development company specializing in products derived from natural substances such as probiotic bacteria, plant extracts and minerals.
Under the new agreement, Zuellig Pharma will undertake comprehensive activities, including product registration, sales and marketing, and warehousing and distribution (W&D), to launch OMNi-BiOTiC®, one of Institut AllergoSan’s world-leading probiotic brands, in key Asian markets.
"Our healthcare consumer products business will be one of our company's key growth drivers over the next few years and this partnership represents a significant step in our commitment to deliver innovative healthcare solutions to the people of Asia. In the fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered by our commercialization division ZP Therapeutics will help our partners to rapidly expand their presence and meet the increasing consumer demand for gut health products in this region. Together with Institut AllergoSan, we will use our combined expertise to improve people's well-being and advance our mission to facilitate access to healthcare.said John Graham, Group CEO of Zuellig Pharma.
"We are committed to helping people in Asia achieve a healthier, more vital self and offer medically relevant probiotics that have been developed for specific indications and deliver clinically proven results. OMNi-BiOTiC® is the best-selling probiotic brand in the entire German-speaking market such as Austria, Germany and Switzerland. We look forward to working closely with Zuellig Pharma to make these innovative probiotics available to anyone in Asia who wants to lead an active, healthy life“, adds Anita Frauwallner, founder and CEO of Institut AllergoSan.
Zuellig Pharma plans to launch OMNi-BiOTiC® in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets such as Thailand.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia with a mission to improve access to healthcare. We provide world-class services to support the growing healthcare needs in this region. Founded a hundred years ago, our company has grown into a billion-dollar company covering 16 markets with over 12.000 employees. Our employees serve more than 200.000 medical facilities and work with over 450 manufacturers, including the 20 largest pharmaceutical companies in the world.
ZP Therapeutics, a division of Zuellig Pharma, is the healthcare industry's preferred commercialization partner with offices in 13 countries in Asia and over 2.500 employees. As a catalyst for improving patient experience and health through absolute excellence, robust commercial capabilities and strong ethical principles, ZP Therapeutics is a trusted partner in expanding patient access and delivering innovation to the healthcare community.
For more information, please visit: https://www.zuelligpharma.com/
About the AllergoSan Institute
The AllergoSan Institute, based in Graz, Austria, was founded in 1991 by a group of integratively thinking doctors and pharmacists together with Mag. Anita Frauwallner. Since then, the company has been involved in the scientific research and development of products made from natural substances such as probiotic bacteria, fiber, micronutrients and plant extracts. Through the intensive collaboration of the AllergoSan Institute with recognized scientists from medicine, pharmacy and microbiology, it was possible to build a renowned research and competence center for the largest organ in the human body - the intestine. This has resulted in the product series OMNi-BiOTiC®, OMNi-LOGiC® and META-CARE® as well as OMNi-POWER®.
It was the true pioneering spirit that led Anita Frauwallner to take a largely unknown path more than 30 years ago: she dedicated her life to microbiome research and the development of innovative, medically relevant probiotics. This spirit has led to OMNi-BiOTiC® now being ranked 3rd worldwide and 1st in the probiotics market in the German-speaking countries of Europe and in numerous other countries. (Source: IQVIA OTC Global Insights 2023, 03F1/A7F, IQVIA OTC Audits / Public Price in EUR.)
Contact and further information
Institute AllergoSan Pharmaceutical Products Research and Sales GmbH
PR & Communication Management
Jurgen Teuschler
Email: pr@allergosan.at
Phone: + 43 316 405 305 127
